share_log

Clearmind Medicine | 20-F/A: Registration statement / Annual report / Transition report (Amendment)

Clearmind Medicine | 20-F/A: Registration statement / Annual report / Transition report (Amendment)

Clearmind Medicine | 20-F/A：年度報告/過渡報告/註冊聲明(修正)
SEC announcement ·  03/18 17:22
Moomoo AI 已提取核心訊息
Clearmind Medicine Inc., a clinical-stage pharmaceutical company, has filed its annual financial report for the fiscal year ended October 31, 2023. The report details the company's financial position, business developments, and future plans. Financial Performance: Clearmind Medicine reported a net loss of $8,620,837 for the year, with comprehensive loss reflecting the same figure. The company has not generated any revenues and has a negative cash flow from operations of $6,301,472. The accumulated deficit as of October 31, 2023, stands at $18,768,063. Business Development: Clearmind Medicine is focused on the development of psychedelic medicines to address health problems. The company's research and development activities are primarily conducted in Israel. Future Plans: Clearmind Medicine plans to continue its clinical trials and research activities. The company has recently completed a public offering and expects to use the net proceeds to fund its operations and development plans. The company's financial statements have been prepared assuming the continuation of the business as a going concern.
Clearmind Medicine Inc., a clinical-stage pharmaceutical company, has filed its annual financial report for the fiscal year ended October 31, 2023. The report details the company's financial position, business developments, and future plans. Financial Performance: Clearmind Medicine reported a net loss of $8,620,837 for the year, with comprehensive loss reflecting the same figure. The company has not generated any revenues and has a negative cash flow from operations of $6,301,472. The accumulated deficit as of October 31, 2023, stands at $18,768,063. Business Development: Clearmind Medicine is focused on the development of psychedelic medicines to address health problems. The company's research and development activities are primarily conducted in Israel. Future Plans: Clearmind Medicine plans to continue its clinical trials and research activities. The company has recently completed a public offering and expects to use the net proceeds to fund its operations and development plans. The company's financial statements have been prepared assuming the continuation of the business as a going concern.
臨床階段的製藥公司Clearmind Medicine Inc. 已提交了截至2023年10月31日的財年的年度財務報告。該報告詳細介紹了公司的財務狀況、業務發展和未來計劃。財務業績：Clearmind Medicine公佈的年度淨虧損爲8,620,837美元，綜合虧損反映了相同的數字。該公司沒有產生任何收入，運營現金流爲負6,301,472美元。截至2023年10月31日，累計赤字爲18,768,063美元。業務發展：Clearmind Medicine專注於開發迷幻藥物，以解決健康問題。該公司的研發活動主要在以色列進行。未來計劃：Clearmind Medicine計劃繼續其臨床試驗和研究活動。該公司最近完成了公開募股，預計將使用淨收益爲其運營和發展計劃提供資金。該公司的財務報表是在假設業務持續經營的情況下編制的。
臨床階段的製藥公司Clearmind Medicine Inc. 已提交了截至2023年10月31日的財年的年度財務報告。該報告詳細介紹了公司的財務狀況、業務發展和未來計劃。財務業績：Clearmind Medicine公佈的年度淨虧損爲8,620,837美元，綜合虧損反映了相同的數字。該公司沒有產生任何收入，運營現金流爲負6,301,472美元。截至2023年10月31日，累計赤字爲18,768,063美元。業務發展：Clearmind Medicine專注於開發迷幻藥物，以解決健康問題。該公司的研發活動主要在以色列進行。未來計劃：Clearmind Medicine計劃繼續其臨床試驗和研究活動。該公司最近完成了公開募股，預計將使用淨收益爲其運營和發展計劃提供資金。該公司的財務報表是在假設業務持續經營的情況下編制的。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息